Product Name | J9 |
Description |
Glucocorticoid resistance inhibitor |
Purity | 99.90% |
Molecular Formula | C12H12N4 |
Molecular Weight | 212.26 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Blue Ice or 4ºC |
Product Type | Inhibitor |
Solubility | Soluble in CDCI3 |
Source | Synthetic |
Appearance | White Solid |
SMILES | NC1=NC(C2CC2)=C(C3=CC=NC=C3)C=N1 |
InChI | InChI=1S/C12H12N4/c13-12-15-7-10(8-3-5-14-6-4-8)11(16-12)9-1-2-9/h3-7,9H,1-2H2,(H2,13,15,16) |
InChIKey | PQLYPFZAOUDDHB-UHFFFAOYSA-N |
Safety Phrases |
Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection |
Cite This Product | J9 (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-182) |
Alternative Names | 4-cyclopropyl-5-(pyridin-4-yl)pyrimidin-2-amine |
Research Areas | Cancer, Cell Signaling |
PubChem ID | PMC4094258 |
Scientific Background | J9 is a small molecule that enhances glucocorticoid receptor expression, thereby sensitizing T-cell acute lymphoblastic leukemia (T-ALL) cells to dexamethasone. While primarily studied in oncology, its mechanism of modulating steroid receptor pathways may have implications in neuroinflammation and stress-related neural disorders. Glucocorticoid signaling plays a role in brain function and resilience to stress, suggesting that J9 could be explored for its potential to modulate neuroendocrine responses in psychiatric and neurodegenerative conditions. |
References | 1. Cantley A.M., et al. (2014) ACS Medicinal Chemistry Letters 5.7: 754-759. |
Reviews
There are no reviews yet.